Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents

Valeria Santini*, António Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo Del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert HoenekoppC. L. Beach, Pierre Fenaux

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

181 Citações (Scopus)

Impressão digital

Pesquise nos tópicos de investigação de “Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents”. O conjunto dos tópicos formam uma impressão digital única.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science